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Objectives. In patients with chest pain suggestive of variant 
angina, we performed this prospective study to test the specificity 
and diagnostic validity of ergonovine echocardiography (detection 
of regional wall motion abnormality during bedside rgonovine 
challenge) as a screening procedure before coronary angiography. 
Background. Spasm provocation test outside the catheteriza- 
tion room has generally not been accepted as a safe diagnostic 
method. 
Methods. Ergonovine chocardiography was performed in 80 
consecutive patients with chest pain syndrome after confirmation 
of negative treadmill or normal stress myocardial perfusion scan 
results using thallium-201. A bolus of ergonovine maleate was 
injected at 5-rain intervals up to a total cumulative dosage of 
0.35 mg with echocardiographic monitoring of left ventricular wall 
motion. A 12-lead electrocardiogram (ECG) was also recorded 
every 3 min after each ergonovine injection. Positive test results 
were development of regional wall motion abnormalities or tran- 
sient ST segment elevation or depression >0.1 mV in any single 
lead of the 12-lead ECG. Coronary angiography was undertaken 
within 2 -+ 4 days (mean +- SD) after ergonovine echocardiogra- 
phy, and the spasm provocation test with acetyleholine orergono- 
vine was performed in patients with normal angiographie findings 
or lumen diameter narrowing < 70%. 
Results. On the basis of angiographic criteria, 56 patients had 
coronary vasospasm; this finding was later ruled out in 19 
patients with near-normal angiographic results by a negative 
response on the spasm provocation test. In the remaining five 
patients, coronary spasm provocation was not performed because 
they revealed a high degree of fixed stenosis (lumen diameter 
narrowing 97 -+ 4%). Ergonovine chocardiography could diag- 
nose coronary vasospasm before angiography, with a sensitivity of 
91% (51 of 56 patients, 95% confidence interval [CI] 84% to 98%) 
and specificity of 88% (21 of 24 patients, 95% CI 75% to 100%). Of 
53 patients howing regional wall motion abnormalities during 
ergonovine echocardiography, characteristic ST segment elevation 
in the simultaneously recorded ECG was observed in only 20 
(38%). There were no complications, including myocardial infarc- 
tion or fatal arrhythmia, during the test. 
Conclusions. Ergonovine chocardiography before coronary 
angiography is safe and can be used as a reliable diagnostic 
screening test for coronary vasospasm in patients with negative 
treadmill or normal stress myocardial perfusion scan results. 
These findings uggest that invasive coronary angiography can be 
avoided in selected patients for the diagnosis of vasospastic 
angina. 
(J Am Coil Cardiol 1996;27:1156-61) 
The usual diagnostic method for coronary artery spasm in- 
cludes an invasive provocation of spasm after coronary angio- 
graphic onfirmation of the absence of a high degree of fixed 
atherosclerotic stenosis (1-3). Because of the potential fatal 
risk of the spasm provocation test and the advantage of 
intracoronary injection of nitroglycerin the catheterization 
laboratory, spasm provocation testing outside the catheteriza- 
tion laboratory isnot accepted as a safe diagnostic method by 
most clinicians. 
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Recently, we reported (4) that a bedside rgonovine prov- 
ocation test with two-dimensional echocardiographic monitor- 
ing of left ventricular regional wall motion (ergonovine echo- 
cardiography) can be used as a safe and reliable noninvasive 
diagnostic method in patients with near-normal ngiographic 
findings. However, in that study, coronary angiography was 
performed before ergonovine chocardiography to exclude 
patients with severe atherosclerotic stenosis; thus, the safety of 
ergonovine chocardiography before coronary angiography 
was not tested. The aim of the present study, therefore, was to 
establish the safety and diagnostic validity of ergonovine cho- 
cardiography as a screening test for vasospastic angina before 
invasive angiography in patients with chest pain syndromes. 
Methods  
Patients. Patients with chest pain syndromes uggesting 
variant angina and negative xercise lectrocardiographic test 
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or normal dipyridamole-thallium-201 myocardial perfusion 
scan results were included in the study. Exclusion criteria 
included a history of myocardial infarction; clinical presenta- 
tion of unstable angina; and bundle branch block or rhythm 
disturbances, including atrial fibrillation. 
From March 1993 to June 1994, 80 consecutive patients 
were enrolled in the study (mean [+SD] age 53 + 10 years, 
range 33 to 75; 56 men, 24 women). After discontinuation f 
cardioactive drugs for at least 5 half-lives, except for applica- 
tion of sublingual nitroglycerin as needed, all patients under- 
went the same diagnostic workup according to the following 
protocol. After written informed consent had been given, an 
exercise electrocardiographic (ECG) test or dipyridamole- 
thallium scan was done to exclude significant fixed stenotic 
disease. Treadmill test results were negative in 55 patients, 
and 15 patients had equivocal exercise ECG but normal 
dipyridamole-thallium myocardial perfusion scan results. 
Dipyridamole-thallium scanning only was performed in 10 
patients with poor exercise capacity and revealed normal 
myocardial perfusion. During the brief hospital period (usually 
3 or 4 days) before coronary angiography, spontaneous coro- 
nary spasm with symptoms and ST segment elevation were 
documented in only six patients (8%). 
Ergonovine chocardiography. Ergonovine chocardiogra- 
phy with two-dimensional echocardiographic monitoring of 
left ventricular regional wall motion was done as described 
previously (4). An intravenous line was placed in the upper 
arm, and noninvasive blood pressure and lead II of the ECG 
were monitored uring the entire procedure. 
At 5-min intervals abolus injection of ergonovine (0.025 or 
0.05 rag) was administered intravenously until the appearance 
of a positive response or a total dose of 0.35 mg was reached. 
The 12-lead ECG was recorded 3 rain after each ergonovine 
injection, and left ventricular wall motion was monitored 
continuously atstandard parasternal long- and short-axis views 
and apical four- and two-chamber views with a 2.5-MHz probe 
(Sonos 1000, 21200C, Hewlett-Packard). Regional wall motion 
was analyzed by a side by side continuous cine-loop display 
method with a commercially available quad system (CineView 
Plus, Freeland Systems) by two experienced echocardiog- 
raphers (J.K.S., D.H.K.). Regional wall motion abnormality was 
generally used to describe any segment graded dyskinetic, 
akinetic or hypokinetic. Positive criteria for the bedside er- 
gonovine test included the appearance of transient ST segment 
elevation or depression >0.1 mV at 0.08 s after the J point 
(ECG criteria) or reversible wall motion abnormality by two- 
dimensional echocardiography (echocardiographic criteria). 
The criteria for terminating the test were as follows: positive 
response defined as ECG or echocardiographic criteria, total 
cumulative dose of 0.35 mg ergonovine or development of
significant arrhythmia or changes in vital signs (systolic blood 
pressure ->200 or -<90 mm Hg). An intravenous bolus in- 
jection of nitroglycerin (0.25 mg) and sublingual nitroglycerin 
(0.6 rag) was given as soon as a positive response (ECG or 
echocardiographic criteria) was detected or at the end of a test 
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Figure 1. Diagram showing assignment of 16 segments to specific 
coronary arteries during ergonovine echocardiography (14). ANT = 
anterior; INF = inferior; LAT = lateral; LAX = long-axis view; 
PM = papillary muscle; POST = posterior; SAX = short-axis view; 
SEPT = septal; 2C = two-chamber view; 4C = four-chamber view. 
with a negative response. Sublingual nifedipine (10 mg) was 
also administered for possible delayed effects of ergonovine. 
The territory of coronary vasospasm was tentatively diag- 
nosed according to segments that developed regional wall 
motion abnormalities during ergonovine echocardiography 
(Fig. 1) and comparison with coronary angiographic results. 
Figure 2 shows one representative example of ergonovine 
echocardiography according to our study protocol. 
Coronary angiography and spasm provocation test. After 
ergonovine chocardiography, all patients underwent diagnos- 
tic coronary angiography with the conventional Judkins tech- 
nique. Patients with a high degree of atherosclerotic stenosis 
(->70% lumen diameter) were diagnosed as having fixed 
disease and were excluded from the spasm provocation test. In 
patients with normal angiographic results or lumen diameter 
narrowing <70% without spontaneous spasm, a provocative 
pharmacologic test for coronary artery spasm was done using 
intravenous (1), intracoronary ergonovine (5) or intracoronary 
acetylcholine (6), according to the methods described else- 
where. The appearance of total or subtotal occlusion of a 
major coronary artery associated with ST segment elevation or 
depression on the ECG or chest pain, or both, was considered 
to be a manifestation f spasm. 
In patients with vasospastic angina, the disease activity was 
assessed clinically according to the frequency of chest pain 
attacks before hospital admission (4); patients with chest pain 
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Figure 2. Representative example ofergonovine echocardiography (A 
to D) and coronary angiography (E and F) in a 53-year old man with 
rest chest pain in the early morning. Treadmill test results were 
negative up to stage 4of the Bruce protocol, and ergonovine echocar- 
diography was done. Left ventricular wall motion at end-systole 
recorded inthe parasternal short-axis view was demonstrated in quad 
screen format. A, Basal status. B, Left ventricular wall motion after 
ergonovine injection of 0.05 mg. Note regional loss of systolic myocar- 
dial thickening in the midinferior segment with an ergonovine dose of 
0.1 mg (C) and recovery of regional wall motion abnormality with 
nitroglycerin (D), a finding suggestive of myocardial ischemia n the 
right coronary artery territory due to coronary vasospasm. Coronary 
angiogram taken 2days later evealed a normal right coronary artery 
(E), and intracoronary injection of acetylcholine (ACH) provoked 
total occlusion of the proximal right coronary artery (F), which was 
compatible with coronary vasospasm. 
five times or more a week were classified as having high disease 
activity, whereas those without his occurrence were consid- 
ered to have low disease activity. Patients with ->50% lumen 
diameter narrowing of the epicardial coronary artery and 
showing superimposed coronary artery spasm on or near the 
stenotic lesion were classified as having mixed disease. Patients 
with coronary artery spasm documented at normal or near- 
normal coronary arteries were considered tohave pure spasm. 
Statistical analysis. Data are expressed as the mean 
value _+ SD. The overall sensitivity and specificity of ergono- 
vine echocardiography were calculated from 2 × 2 tables 
according to the invasive angiographic riteria. Ninety-five 
percent confidence intervals were calculated with binomial 
distribution. 
Resul ts  
Ergonovine echoeardiography. Four (5%) of 80 patients 
had a poor echocardiographic window, and monitoring of wall 
motion abnormality with two-dimensional echocardiography 
was impossible. In these patients, ST segment changes on the 
12-lead ECG during ergonovine provocation was the only 
diagnostic riterion of coronary artery spasm (7). Two patients 
had negative test results, and one patient revealed character- 
istic ST segment elevation at the total cumulative dosage of 
0.15 mg. Another patient complained of chest pain with the 
ergonovine dosage of 0.05 mg without definite ECG changes, 
but further administration f ergonovine was not done because 
of worsening of chest pain; in this patient, ergonovine cho- 
cardiography was incomplete but the response was considered 
negative because of the failure to demonstrate d finite objec- 
tive evidence of myocardial ischemia. 
In the remaining 76 patients, two-dimensional echocardio- 
graphic monitoring of left ventricular wall motion was possible 
during ergonovine chocardiography. Fifty-three of 76 patients 
revealed wall motion abnormality with ergonovine provocation 
(mean ergonovine dose 160 _+ 117 p~g). Regional wall motion 
abnormalities were detected in the left anterior descending 
coronary artery territory in 27 patients (50%), the right coro- 
nary artery in 20 (37%), the left circumflex coronary artery in 
3 (7%), the left anterior descending and right coronary arteries 
in 2 and the left anterior descending and left circumflex 
coronary arteries in 1. 
Among 53 patients with regional wall motion abnormalities 
on two-dimensional echocardiography, 20 (38%) showed char- 
acteristic ST segment elevation in the simultaneously recorded 
12-lead ECG, 4 (8%) showed ST segment depression, and 7 
(13%) had minor T wave changes without ST segment dis- 
placement. In 22 patients (42%), two-dimensional echocardi- 
ography detected wall motion abnormalities without any ECG 
changes uggestive ofmyocardial ischemia. During ergonovine 
echocardiography in 80 consecutive patients, no serious 
procedure-related arrhythmia or myocardial infarction oc- 
curred. 
Coronary angiography with spasm provocation. Diag- 
nostic coronary angiography was performed 2 + 4 days after 
ergonovine chocardiography in all 80 patients. Five patients 
(6%) without a spasm provocation test were diagnosed as 
having fixed disease because of lumen diameter narrowing of 
major epicardial coronary arteries >70% (mean 97 + 4%). 
Spontaneous spasm was documented in 12 patients (15 %). The 
remaining 63 patients underwent a pharmacologic provocative 
test for coronary artery spasm. Intracoronary ergonovine was 
administered in 26 patients, intracoronary acetylcholine in 18, 
intravenous ergonovine in 14 and consecutive intracoronary 
acetylcholine and ergonovine in 5. 
Diagnostic oronary angiography and the spasm provoca- 
tion test revealed coronary artery spasm in 56 patients, signif- 
icant fixed disease in 5 and near-normal findings without 
evidence of spasm in 19 (Table 1). Among the 56 patients with 
documented coronary artery spasm, 46 had pure spasm, 10 had 
mixed disease with a mean lumen diameter narrowing of 60 + 
7%, and 10 (18%) had multivessel spasm. During the spasm 
provocation test in the catheterization laboratory, marked 
sinus bradycardia developed in one patient and transient 
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Table 1. Final Results of Ergonovine Echocardiography and 
Coronary Angiography With Spasm Provocation Test 
Coronary Angiography 
Vasospasm + Vasospasm - 
Erg Echo Pure Spasm Mixed Normal Fixed Disease 
+ (n = 54) 42 9 1 2 
- (n = 26) 4 1 18 3 
Erg Echo = ergonovine echocardiography; Fixed Disease - lumen diameter 
narrowing --70%; Mixed = moderate lumen diameter narrowing (>50%, 
<70%) with superimposed coronary vasospasm; Normal = no fixed disease, 
negative spasm provocation test results; Pure Spasm = coronary vasospasm in
normal or near-normal (lumen diameter narrowing <50%) coronary artery; + = 
positive results; - = negative results. 
nonsustained ventricular tachycardia nanother, but no serious 
complications, including death or myocardial infarction, oc- 
curred. Results of ergonovine chocardiography, diagnostic 
coronary angiography and spasm provocation tests are sum- 
marized in Table 1. 
According to the coronary angiographic criteria, ergono- 
vine echocardiography for diagnosis of coronary artery spasm 
before invasive angiography had a sensitivity of 91% (51 of 56 
patients, 95% confidence interval [CI] 84% to 98%), a speci- 
ficity of 88% (21 of 24, 95% CI 75% to 100%), a positive 
predictive value of 94% (51 of 54) and a negative predictive 
value of 81% (21 of 26). Of three patients with false positive 
results on ergonovine chocardiography, two had severe fixed 
atherosclerotic stenosis requiring revascularization. In the two 
patients with fixed coronary artery disease, treadmill or thal- 
lium perfusion scan did not demonstrate myocardial ischemia, 
but ergonovine echocardiography revealed either ECG 
changes or regional wall motion abnormalities in the territories 
of significant fixed coronary disease. Of five patients with false 
negative results on ergonovine chocardiography, one had a 
poor echocardiographic window, and ergonovine chocardiog- 
raphy was terminated because of worsening chest pain; the 
remaining four patients had coronary artery spasm with low 
disease activity (Table 2). 
Documented sites of coronary vasospasm during ergono- 
vine echocardiography and diagnostic oronary angiography 
are summarized in Table 3. Among 27 patients with wall 
motion abnormality in the left anterior descending coronary 
artery territory during ergonovine echocardiography, 24 
showed angiographic evidence of spasm in the corresponding 
artery. One patient showed a high degree of fixed stenosis on 
the basal angiogram, and coronary vasospasm in the proximal 
left circumflex coronary artery was observed in another. In one 
other patient, spontaneous spasm developed in the proximal 
right coronary artery requiring infusion of nitroglycerin, and 
pharmacologic provocation testing was not done. Wall motion 
abnormalities in the right coronary artery territory were 
present in 20 patients during ergonovine chocardiography, 
and angiographic spasm in the same territory was present in 17 
at catheterization. Of the remaining three patients, one had 
false positive results on ergonovine chocardiography, one 
developed spontaneous vasospasm in the distal left circumflex 
coronary artery, and one developed simultaneous coronary 
artery spasm in the left anterior descending and left circumflex 
coronary arteries with intracoronary injection of acetylcholine, 
which made a spasm provocation test of the right coronary 
artery redundant because of nitroglycerin administration. 
In five patients with fixed atherosclerotic disease, exercise 
ECG and thallium perfusion scan results were negative, and 
they underwent ergonovine chocardiography. Two of these 
patients had positive rgonovine provocation results according 
to the ECG or echocardiographic criteria. The other three 
patients did not develop ECG changes or regional wall motion 
abnormality with ergonovine up to a total cumulative dose of 
0.35 mg. None of these five patients with significant coronary 
artery stenosis (mean lumen diameter narrowing 97 _+ 4%, 
range 90% to 100%) experienced serious complications during 
ergonovine chocardiography. 
Discuss ion 
Diagnostic validity of ergonovine chocardiography. Es- 
tablishment of a noninvasive and reliable method of diagnos- 
ing coronary artery spasm would be useful in the management 
of patients with variant angina because such a method can be 
used for screening patients with chest pain syndromes, and the 
therapeutic efficacy of prescribed rugs can be evaluated. In 
the present study, the sensitivity and specificity of ergonovine 
echocardiography fordiagnosis of coronary artery spasm were 
91% and 88%, respectively, including those patients with a 
poor echocardiographic window. The specificity of the test was 
Table 2. Clinical Data for Five Men With False Negative Results on Ergonovine Echocardiography 
Pt Ergonovine Echocardiography 
No. Age (yr) Activity Chest Pain ECG RWMA CAG Spasm Site 
1 51 Low - - - Normal mLAD, dRCA 
2 54 Low . . . .  Normal pRCA 
3 52 Low - - Normal mLAD, dRCA 
4 58 Low - - - Normal dRCA 
5 45 High + -*  pLAD 60% pLAD 
*Poor echocardiographic window made definite demonstration f regional wall motion abnormalities (RWMA) impossible. CAG = diameter narrowing (%) by 
coronary angiography; d = distal; ECG = electrocardiogram; LAD = left anterior descending coronary artery; Low = chest pain attack less than five times a week; 
- = no change, negative test results; m = mid; p = proximal; Pt = patient; RCA = right coronary artery. 
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Table 3. Comparison fDocumented Sites of Spasm During Ergonovine Echocardiography andDiagnostic Coronary Angiography 
Sites of Vasospasm onCoronary Angiography 
pLAD mLAD mLAD pLAD 
+ + + + Fixed 
Erg Echo Main pLAD Diag pLCx pRCA pLCx pLCx dLCx pRCA mRCA dRCA pLCx Normal Disease 
LAD territory 1 16 2 2 2 1 1 1 1 
(n = 27) 
RCA territory. 1 8 7 2 1 1 
(n - 20) 
Diag = diagonal branch; LCx = left circumflex coronary artery; other abbreviations a in Tables 1 and 2. 
somewhat low compared with that in our previous tudy (4). 
This low specificity is due to the fact that in the present study 
we used a noninvasive method to rule out significant fixed 
coronary artery disease, whereas in the previous study coro- 
nary angiography had been performed before the ergonovine 
echocardiography. Two patients with severe fixed coronary 
artery stenosis >90% were inadvertently enrolled in the study 
because of negative stress test results, but these were consid- 
ered false positive results because spasm induction was not 
attempted during coronary angiography. Had we performed 
the spasm provocation, they could have shown positive results. 
Thus, if we exclude the patients with significant fixed disease, 
the specificity of ergonovine chocardiography would increase 
to 94% (17 of 18). 
Of three patients with false positive results on ergonovine 
echocardiography, two had a high degree of fixed stenosis on 
the basal angiogram and showed positive rgonovine chocar- 
diographic results with ST segment displacement on the ECG 
or wall motion abnormalities. These results may be explained 
by some clinical reports demonstrating a high association 
between fixed atherosclerotic lesions and coronary artery 
spasm (8-11). But because the ergonovine provocation test 
results were negative with ergonovine injection up to 0.35 mg 
in the other three patients with a high degree of fixed stenosis, 
coronary artery spasm and fixed stenosis must be considered 
two independent mechanisms evoking myocardial ischemia 
(2,3). 
The term "mixed disease" needs some clarification. The 
aforementioned two patients with a high degree of fixed lumen 
narrowing of epicardial coronary arteries and definite ECG 
changes or regional wall motion abnormalities during ergono- 
vine echocardiography can be considered to have mixed dis- 
ease. However, in the present study we somewhat arbitrarily 
defined mixed disease as superimposed spasm in the presence 
of a moderate degree of fixed stenosis (lumen diameter 
narrowing between 50% and 70%). With different definitions 
of mixed disease, the sensitivity and specificity of a noninvasive 
diagnostic method may change. It would be of interest o 
perform ergonovine provocation i  the patients with significant 
organic stenosis (lumen diameter narrowing >70%) for eval- 
uation of possible association between fixed stenosis and 
coronary vasospasm. 
In stress echocardiography for fixed organic stenosis, it is 
well known that regional wall motion abnormalities on two- 
dimensional echocardiography can accurately predict he sites 
of organic stenosis on coronary angiography (12-14). In the 
present ergonovine chocardiographic studies, wall motion 
abnormalities on two-dimensional echocardiography corre- 
lated well with the vascular territory of the coronary artery that 
had spasm. The rare cases of discordant results may be 
explained by the difficulty of performing a pharmacologic 
provocative test after spontaneous spasm or development of
multivessel spasm. 
Safety of ergonovine chocardiography. We believe that 
the present study confirms the safety of ergonovine chocar- 
diography as a screening diagnostic test for coronary spasm 
that can be done before coronary angiography because there 
were no serious complications among 80 consecutive patients 
with negative stress test results. Because rgonovine chocar- 
diography can detect regional wall motion abnormalities, a 
sensitive marker of myocardial ischemia, even before the 
appearance of chest pain or ECG changes (15,16), it is 
theoretically safer than spasm provocation during catheteriza- 
tion, with the usual 3- or 4-rain wait after each administration 
of drug before performance of repeat angiography. In fact, two 
patients developed marked sinus bradycardia and ventricular 
tachycardia during the spasm provocation test at catheteriza- 
tion but had no complications during ergonovine chocardiog- 
raphy. This finding reinforces the importance and superiority 
of continuous monitoring of ventricular wall motion for safety 
during the spasm provocation test. 
Our results also proved that intracoronary administration f 
nitroglycerin is not an absolute prerequisite for the spasm 
provocation test. Intravenous bolus injection and sublingual 
application of nitroglycerin were effective in safely reversing 
coronary artery spasm in all 54 patients with positive tests on 
ergonovine chocardiography. As pointed out previously, ear- 
lier detection of myocardial ischemia with wall motion moni- 
toring is important for patient safety because ischemic ascade 
can be terminated earlier and the risks associated with pro- 
longed ischemia reduced. Of 53 patients with definite wall 
motion abnormalities, 22 (42%) revealed no ECG changes 
suggestive of myocardial ischemia, which strengthens our 
contention. Safe performance of ergonovine chocardiography 
in the five patients with a high degree of fixed stenosis is 
another demonstration of the importance of wall motion 
abnormality detection and of the safety of this test. 
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Limitations of the study. Poor echocardiographic window 
is one of the inherent limitations of echocardiographic tech- 
niques. In 5 patients, echocardiograpic monitoring of left 
ventricular wall motion was impossible, and in an additional 12 
(15%), left ventricular wall motion could be monitored in only 
two standard views. As has been confirmed in stress echocar- 
diography for fixed organic stenosis (17), observation through 
more than two standard views is usually sufficient for diagnosis 
of wall motion abnormality and prediction of involved territo- 
ries of coronary arteries. Thus, this limitation should not 
significantly alter our conclusions with regard to the diagnostic 
validity of ergonovine chocardiography. 
In our study, both ergonovine and acetylcholine were used 
for provocation of coronary spasm during coronary angiogra- 
phy. Although ergonovine is a more widely used drug for 
spasm provocation, intracoronary acetylcholine is also a valid 
method, as was demonstrated by Yasue et al. (6). 
Ergonovine echocardiography may be insensitive in the 
detection of multivessel spasm. Fujii et al. (18) reported that 
they could diagnose simultaneous multivessel spasm in 30% of 
patients with variant angina using hyperventilation as a spasm 
provocation method. According to the present angiographic 
results, multivessel spasm was diagnosed in 10 (18%) of 56 
patients, but only three were diagnosed as having multivessel 
spasm during ergonovine chocardiography. Definite diagnosis 
of multivessel spasm is a complex problem. The limitation of 
ergonovine echocardiography in the diagnosis of multivessel 
spasm is real, but the same limitation applies to spasm prov- 
ocation during cardiac catheterization unless provocation is 
performed in each artery separately or simultaneous coronary 
angiography is obtained in two coronary arteries. 
Conclusions. Despite the difficulty of monitoring wall mo- 
tion because of a poor echocardiographic window and the 
unproved diagnostic validity of multivessel spasm, ergonovine 
echocardiography is a safe and reliable screening test for 
diagnosis of coronary artery spasm in selected patients with 
chest pain syndromes. Thus, invasive coronary angiography 
and a spasm provocation test during catheterization may be 
unnecessary for diagnosis of vasospastic angina in most pa- 
tients with negative treadmill or normal thallium perfusion 
scan results. 
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